Highest-materiality recent filing
Chemours Q1 net loss widens to $29M; adjusted EBITDA up 2% to $169M
Net sales $1.381B, up 1% YoY; TSS segment posted record Q1 with double-digit Opteon growth.
Shareholders approve 2026 Equity Plan, elect 11 directors at annual meeting
2026 Equity Plan approved with ~96.7% of votes cast; authorizes 6,375,275 shares for issuance.
Chemours issues $700M 7.875% senior notes due 2034; refinances 2027 and 2028 notes
Closed private offering of $700M aggregate principal of 7.875% senior notes due 2034.
Chemours prices $700M of 7.875% senior notes due 2034, upsized from $600M
Issued $700M aggregate principal of 7.875% senior unsecured notes due 2034, upsized from $600M.
Chemours Q4 net loss widens to $47M; full year 2026 outlook: Adj. EBITDA $800M-$900M
Q4 net loss $47M (-$0.31/diluted) vs loss $11M (-$0.08) YoY; adjusted net income $7M ($0.05) vs $14M ($0.09).
Chemours agrees to sell Taiwan land for $360M, proceeds to reduce debt
Total gross cash proceeds of approximately $360 million from sale of former TiO2 site in Kuan Yin, Taiwan.
Chemours Q3 net income $60M vs loss prior year; adjusted EBITDA $195M down 3%
Net income of $60M ($0.40/share) reverses prior-year loss of $32M; adjusted net income $30M ($0.20) vs $61M.
Chemours adopts new executive severance policy with 2.0x multiplier for CEO
CEO severance: 2.0x sum of base salary, target annual incentive, and annualized health care subsidy; other execs 1.0x.
Chemours extends $1.05B term loan to 2032 and secures €180M factoring facility
Extended maturity of $1.05B Term Loan B-3 US$ to Oct 2032 from Aug 2028; margin Term SOFR+3.50%.
Chemours appoints Mary Cranston as Chair, Alister Cowan as Lead Independent Director
Board Chair Dawn Farrell departs to lead Canadian government's Major Projects Office under the Building Canada Act.
Chemours Chair Dawn Farrell resigns effective Sept 2 for Canadian government role
Chair Dawn Farrell notified Board on Aug 29, 2025 of resignation effective Sept 2, 2025.
Chemours Q2 net loss $381M; adjusted EBITDA up 22% to $253M; NJ PFAS settlement reached
Net loss of $381M ($2.54 diluted EPS) vs net income $60M ($0.39) in Q2 2024; adjusted net income $87M ($0.58).
Chemours, DuPont, Corteva agree to $875M NJ PFAS settlement; Chemours share ~$250M PV
Total $875M cash over 25 years; pre-tax PV ~$500M (8% discount); Chemours 50% (~$250M PV).
Chemours Q1 net loss of $4M vs profit $54M; adjusted EBITDA $166M; cuts dividend
Net loss $4M, diluted EPS -$0.03 vs net income $54M, EPS $0.36 YoY.
Chemours annual meeting: supermajority amendment fails, biodiversity proposal defeated
All 12 director nominees elected with 92.8%–98.8% FOR.
Chemours extends receivables facility maturity to 2028, reduces limit to $165M
Maturity date extended from March 31, 2025 to March 31, 2028.
Chemours director Guillaume Pepy will not stand for re-election at 2025 annual meeting
Pepy notified the board on March 9, 2025 of his decision not to seek re-election.
Chemours reports Q4 2024 net loss of $8M, provides FY2025 EBITDA guidance of $825-975M
Q4 Net Sales $1.4B flat YoY; Net Loss $8M ($0.05 diluted) vs prior year loss $18M.
Chemours director Curtis Anastasio not seeking re-election at 2025 annual meeting
Curtis V. Anastasio will not stand for re-election to Chemours' Board at the 2025 Annual Meeting.
Chemours appoints Leslie M. Turner to Board; 2025 annual meeting set for April 22
Leslie M. Turner appointed to Chemours Board effective Feb 19, 2025.
Chemours appoints Google VP Joseph Kava to board, effective Jan 3, 2025
Joseph D. Kava appointed to Chemours board; board size increased from 10 to 11 members.
Chemours reprices €415M Term Loan B-3; margin cut 75 bps to EURIBOR+3.25%
Second Amendment reduces applicable margin on Tranche B-3 Euro Term Loan from EURIBOR+4.00% to EURIBOR+3.25%.
Chemours files 8-K/A to correct exhibits for $600M 8.000% Senior Notes due 2033 offering
Amendment corrects technical error in Exhibits 4.2 and 4.3 from original 8-K filed November 27, 2024.
Chemours reprices $1.07B term loan, margin cut by 50 bps
Margin on Term Loan B-3 US$ Facility reduced from SOFR+3.50% to SOFR+3.00% (or base rate+2.50% to +2.00%).
Chemours closes $600M 8% senior notes due 2033, to redeem €441M 4% notes due 2026
Issued $600M aggregate principal of 8.000% Senior Notes due January 15, 2033 in a private offering.
Chemours prices $600M 8% senior notes due 2033 to refinance 2026 notes
$600M principal of 8.000% senior unsecured notes due 2033 priced in private offering.
Chemours Q3 net loss $27M on $56M impairment; adjusted EPS $0.40; TSS Opteon sales up 21%
Net loss of $27M ($0.18/diluted share) due to $56M non-cash impairment of APM goodwill.
Presentation dated August 2024 filed as Exhibit 99.1; no financial or strategic details extracted from text.
Chemours Q2 net income $70M vs prior loss; adj EBITDA down 36%
Net sales $1.5B (-6% YoY); net income $70M ($0.46 diluted EPS) vs prior-year net loss $376M ($2.52 loss).
Chemours appoints David A. Will as Controller and Chief Accounting Officer
David A. Will appointed Controller and CAO effective August 12, 2024.
Chemours appoints Tony Satterthwaite as independent director, effective June 12, 2024
Satterthwaite appointed to Chemours Board, effective June 12; board size increased from 9 to 10 directors.
Chemours names Shane Hostetter as CFO effective July 1, 2024
Hostetter joins from Quaker Houghton, where he served as CFO since April 2021.
Paused production at Altamira TiO2 facility in Mexico due to severe regional drought.
Chemours shareholders elect all nine director nominees, approve say-on-pay and auditor ratification
All nine director nominees elected with 91.6% to 97.0% of votes cast in favor.
Chemours Q1 earnings: net sales $1.35B (-12% YoY), net income $52M, adj EBITDA $193M
Net sales $1.35B, down 12% YoY; volumes -6%, price -5%.
Chemours CFO Lock resigns amid accounting review; gets extended options, no severance
Resigned as SVP & CFO effective April 23, 2024; no severance, no 2023 or 2024 annual incentive.
On March 9, 2025, Guillaume Pepy notified the Board of Directors (the “Board”) of The Chemours Company (the “Company”) of his decision not to seek re-election to the Board at the Company’s 2025 Annual Meeting of Shareholders, when his current term expires.
On February 13, 2025, Curtis V. Anastasio notified the Board of Directors (the "Board") of The Chemours Company (the "Company") of his decision not to seek re-election to the Board at the Company's 2025 Annual Meeting of Stockholders, when his current term expires.
appointed Leslie M. Turner as a member of the Board, effective February 19, 2025.
On January 3, 2025, the Board of Directors (the “Board”) of The Chemours Company (the “Company”) appointed Joseph D. Kava as a member of the Board, effective January 3, 2025.
On July 23, 2024, David A. Will was appointed as Controller and Chief Accounting Officer (principal accounting officer) of The Chemours Company (the “Company”) effective as of August 12, 2024.
On June 12, 2024, the Board of Directors (the “Board”) of The Chemours Company (the “Company”) appointed Livingston “Tony” Satterthwaite as a member of the Board, effective June 12, 2024.
Mr. Hostetter succeeds Matthew Abbott, who has served as the Interim Chief Financial Officer (principal financial and accounting officer) since February 28, 2024. Mr. Abbott will continue serving as the Company’s Senior Vice President & Chief Enterprise Transformation Officer
On May 31, 2024, the Board of Directors (the “Board”) of The Chemours Company (the “Company”) appointed Shane Hostetter as Chief Financial Officer, effective as of July 1, 2024.
On April 23, 2024, Jonathan S. Lock resigned from all positions with The Chemours Company (the “Company”).
Max materiality 0.80 · Median 0.55 · Most common event leadership